報價延遲最少15分鐘:2026/04/25 18:44 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.642 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.56/-10.80
|
|
企業價值
2.74M
|
| 資產負債 |
|
每股賬面淨值
1.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focusedon advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic braininjury (mTBI), or concussion. |
